七年的治疗与慢性乙型肝炎病毒感染的富马酸替诺福韦酯是

StephenW

Seven Years of Treatment With Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance
	Reported by Jules Levin AASLD 2013 Nov 1-5 Wash DC Patrick Marcellin,1 Edward Gane,2 Naoky Tsai,3 Robert Flisiak,4 Jörg Petersen,5 Selim Gurel,6 Iskren A. Kotzev,7 Raul Aguilar Schall,8 John F. Flaherty,8 Anuj Gaggar,8 Kathryn M. Kitrinos,8 G. Mani Subramanian,8 John G. McHutchison,8 Jacob George,9 Maria Buti10 1Hôpital Beaujon, Clichy, France; 2Auckland City Hospital, Auckland, New Zealand; 3University of Hawaii at Manoa, Honolulu, HI; 4Medical University of Bialystok, Bialystok, Poland; 5University of Hamburg, Hamburg, Germany; 6Uludag Universitesi Tip Fakultesi, Bursa, Gorukle, Turkey; 7University Hospital Sveta Marina, Varna, Bulgaria; 8Gilead Sciences, Inc., Foster City, CA; 9Storr Liver Unit, Westmead Hospital, Sydney, New South Wales, Australia; 10Hospital General Universitari Vall d'Hebron and Networked Biomedical Research Center: Hepatic and Digestive Diseases (CIBERehd), Barcelona, Spain

StephenW

Christine K Kukka, HBVADVOCATE.ORG

. Long-Term Trials Show Tenofovir Effective.
In two trials, tenofovir was shown to be safe and effective over a seven-year treatment period with no signs of drug resistance despite long-term treatment. Studies also showed a relatively low rate of kidney damage or bone loss.

    In one study, 154 patients were treated long-term had the following results:

        54% lost HBeAg

        40% lost HBeAg and developed "e" antibodies
        12% lost surface antigen (HBsAg) and 10% developed surface antibodies--and cleared the infection.

    Control ID 1735577. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. (Abstract #926)

    Tenofovir reduces need for liver transplants: Another study found that tenofovir was so effective in improving liver health, even in patients who had develops severe liver scarring and damage from cirrhosis that it reduced the need for liver transplants in those patients. "Therefore, starting therapy with a potent agent as tenofovir offers reducing the transplantation requirement," they wrote.

    Control ID 1736186. Long-term tenofovir therapy reduces the need for liver transplantation in patients with cirrhosis. (Abstract #1749)

    Tenofovir effective in patients with resistance to multiple antivirals: Tenofovir proved to be effective in 52 patients who had failed to respond to prior treatment due to development of drug resistance to lamivudine, adefovir and entecavir.

    Most of the patients were male and nearly all were HBeAg-positive with high viral loads. After four years of tenofovir treatment, researchers reported that 96.7% had achieved undetectable viral load. Seven of the 48 (14.6%) lost HBeAg and 27 of 31 patients who had elevated ALT levels at the start of treatment achieved normal ALTs.

    Control ID 1734808. Tenofovir rescue therapy after multiple nucleos(t)ide analogue treatment failure in chronic hepatitis B patients. (Abstract #906)

。显示泰诺福韦有效的长期试验。
在两项试验中，替诺福韦被证明是安全和有效的，尽管长期治疗超过7年的治疗期间，无耐药性的迹象。研究还表明，肾损害或骨质流失率相对较低。

    在一项研究中， 154例患者治疗长期的，结果如下：

        54％ HBeAg消失

        失去了40％的HBeAg和发达国家的“e”抗体
        12％失去了表面抗原（HBsAg ）和10％开发的表面抗体 - 清除感染。

    控制ID 1735577 。 7年替诺福韦治疗慢性乙肝病毒感染是安全的，耐受性良好，并伴有持续病毒学，生化和血清学反应没有检测到电阻。 （摘要＃ 926 ）

    泰诺福韦减少需要肝移植的另一项研究发现，替诺福韦是如此有效改善肝脏健康，甚至谁开发疤痕和严重肝损害，它减少了在这些患者需要肝移植的肝硬化患者。 “因此，一个强有力的代理人替诺福韦治疗提供降低了移植的要求， ”他们写道。

    控制ID 1736186 。长期替诺福韦治疗可减少肝硬化患者需要进行肝移植。 （摘要编号1749 ）

    患者耐多抗病毒药物泰诺福韦泰诺福韦有效52例患者没有回应治疗前由于拉米夫定，阿德福韦和恩替卡韦耐药性的发展证明是有效的。

    大多数患者是男性，几乎所有的HBeAg阳性的病毒载量高。替诺福韦治疗四年后，研究人员报告说，检测不到病毒载量已达到96.7％ 。七， 48 （14.6％）失去HBeAg和27 31 ALT水平升高的患者在治疗开始实现正常的低价竞标。

    控制ID 1734808 。泰诺福韦抢救治疗后，多个核苷（T） IDE模拟治疗失败的慢性乙型肝炎患者。 （摘要＃906 ）

一叶凡尘

麻烦StephenW或者其他专业人氏分析解答一下：“74％ of patients with cirrhosis no longer had cirrhosis at year 5, 74%肝硬化患者在5年治疗后没有再有肝硬化。”
这句话怎么理解？原来的肝硬化没有了，肝脏恢复正常;还是肝硬化保持原状没有进一步的发展？不管怎么说是个好消息，谢谢分享。

StephenW

回复 一叶凡尘 的帖子

“74％ of patients with cirrhosis no longer had cirrhosis at year 5, 74%肝硬化患者在5年治疗后没有再有肝硬化。”
这句话怎么理解？原来的肝硬化没有了 ----是的。肝硬化是肝纤维化阶段   > =S4. 如果纤维化
阶段变成 < S4，患者不再是肝硬化，有些可能仍然有纤维化.

"96% of all patients had either improvement or no worsening of firbrosis"

96% 的患者 纤维化原状没有进一步的发展 或 有改善.

咬牙硬挺

感谢分享

一叶凡尘

谢谢StephenW的专业解释。

010pi

感谢分享